Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (31-40 of 101) with videos related to

Pageof 11
Sort By:
British Journal of Haematology|July 8, 2022
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotypePatrick Harrington, Richard Dillon, Deepti Radia, et al.
British Journal of Haematology|November 7, 2020
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasmsSamah Alimam, Jessica Ann Timms, Claire N Harrison, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Blood|March 12, 2020
Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosisAileen G Rowan, Richard Dillon, Aviva Witkover, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
British Journal of Haematology|March 15, 2021
Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Patrick Harrington, Claire N Harrison, Richard Dillon, et al.
Leukemia|February 6, 2021
Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesisRichard Dillon, Matthew J Ahearne, Lynn Quek, et al.
Haematologica|April 21, 2019
Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumabLucy B M Cook, Maria Antonietta Demontis, Sophie Sagawe, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
British Journal of Haematology|May 22, 2023
Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8<sup>+</sup> T-cell expansion, significant cytokine release syndrome and induction of disease remissionRoisin Borrill, Kay Poulton, Laura Kusyk, et al.
Pageof 11

Showing results (31-40 of 101) with videos related to

Sort By:
Pageof 11
British Journal of Haematology|July 8, 2022
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotypePatrick Harrington, Richard Dillon, Deepti Radia, et al.
British Journal of Haematology|November 7, 2020
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasmsSamah Alimam, Jessica Ann Timms, Claire N Harrison, et al.
Haematologica|January 26, 2023
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemiaPatrick Harrington, Richard Dillon, Deepti Radia, et al.
Blood|March 12, 2020
Evolution of retrovirus-infected premalignant T-cell clones prior to adult T-cell leukemia/lymphoma diagnosisAileen G Rowan, Richard Dillon, Aviva Witkover, et al.
Blood|November 1, 2024
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AMLCurtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, et al.
British Journal of Haematology|March 15, 2021
Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Patrick Harrington, Claire N Harrison, Richard Dillon, et al.
Leukemia|February 6, 2021
Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesisRichard Dillon, Matthew J Ahearne, Lynn Quek, et al.
Haematologica|April 21, 2019
Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumabLucy B M Cook, Maria Antonietta Demontis, Sophie Sagawe, et al.
BMC Cancer|November 15, 2022
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trialRichard Dillon, Shanna Maycock, Aimee Jackson, et al.
British Journal of Haematology|May 22, 2023
Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8<sup>+</sup> T-cell expansion, significant cytokine release syndrome and induction of disease remissionRoisin Borrill, Kay Poulton, Laura Kusyk, et al.
Pageof 11